Culmination Bio Raises $10M From Amgen Ventures and Merck Global Health Innovation Fund to Bring Longitudinal Health Data to Biopharma.

Our Funding from Amgen Ventures and Merck GHI: Igniting Data-Driven Healthcare Research with Culmination Bio’s Data Repository

Culmination’s CEO, Dr. Lincoln Nadauld spoke at the Illumina Genomics Forum in San Diego about healthcare innovation.

Culmination is changing the world by becoming the trusted source for healthcare insights and discoveries to improve lives.

Casey Frankenberger, PhD is Culmination’s SVP, Head of Data, leading the development of our Intelligence Platform.